New research from Charles Rivers Associates for EFPIA demonstrates that a voucher system designed to drive research and development (R&D) into new antibiotics would cost Member States 45% less than previously estimated by the European Commission.
Antimicrobial resistance (AMR) is one of the world’s most pressing health emergencies.Yet despite the urgent need, private investment in antimicrobial R&D is limited. To prevent bacteria developing resistance to existing treatments, the aim with any new antibiotic is to use it as little as possible - not an attractive proposition for investors.
The transferable exclusivity voucher (TEV) is designed to address this challenge by rewarding the discovery of novel antibiotics without requiring upfront public investment.
